Emerging treatments for classical myeloproliferative neoplasms (original) (raw)
Revised Myeloproliferative Neoplasms Working Group Consensus Recommendations for Diagnosis and Management of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
Hari Suma
Indian Journal of Medical and Paediatric Oncology, 2018
View PDFchevron_right
Novel therapeutics in myeloproliferative neoplasms
John Mascarenhas
Journal of Hematology & Oncology
View PDFchevron_right
Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis
kate burbury
Blood, 2020
View PDFchevron_right
Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
J Mariano Anto Bruno Mascarenhas
Current Medicinal Chemistry, 2012
View PDFchevron_right
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
Vibe Skov
Haematologica
View PDFchevron_right
Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
John Mascarenhas
Clinical Cancer Research, 2012
View PDFchevron_right
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis
Francesco Mendicino
Future oncology (London, England), 2015
View PDFchevron_right
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
Heike Pahl
Annals of Hematology
View PDFchevron_right
Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia
Hemant Malhotra
Indian Journal of Medical and Paediatric Oncology, 2015
View PDFchevron_right
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis
Vibe Skov
Cancer medicine, 2018
View PDFchevron_right
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
Mary McMullin
British Journal of Haematology, 2014
View PDFchevron_right
An Exciting New Era in the Treatment of Myeloproliferative Neoplasms
Rita Assi
Oncology & Hematology Review (US), 2016
View PDFchevron_right
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group
Caroline Hamm
Clinical Lymphoma Myeloma and Leukemia, 2015
View PDFchevron_right
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial
Anita Szőke
JAMA oncology, 2018
View PDFchevron_right
New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options
Domenico Penna
Medicina, 2021
View PDFchevron_right
Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib
Leonardo Boiocchi
Annals of Hematology, 2015
View PDFchevron_right
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Sanjay Akhani
Future Oncology
View PDFchevron_right
The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases
sezgin etgül
International Journal of Hematology and Oncology, 2016
View PDFchevron_right
Real-life ruxolitinib experience in intermediate-risk myelofibrosis
I. Kaygusuz
Blood Research, 2021
View PDFchevron_right
Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms
Marie Sebert, Anne-Marie Ronchetti, Emmanuel Raffoux
British Journal of Haematology, 2015
View PDFchevron_right
‘JAK–ing’ up the treatment of primary myelofibrosis
Rita Assi
Current Opinion in Hematology, 2017
View PDFchevron_right
Development of ruxolitinib as a myelofibrosis therapy
Abdulkareem Almomen
Journal of Applied Hematology, 2013
View PDFchevron_right
Ruxolitinib in the treatment of patients with myelofibrosis — questions and answers
Marta Sobas
Oncology in Clinical Practice
View PDFchevron_right
A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
John Mascarenhas
Blood, 2013
View PDFchevron_right
Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
Shashank Cingam
Journal of Blood Medicine, 2016
View PDFchevron_right
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Richard Silver
Journal of hematology & oncology, 2017
View PDFchevron_right
Chronic myeloproliferative neoplasms: a collaborative approach
Alessandro Vannucchi
Mediterranean journal of hematology and infectious diseases, 2010
View PDFchevron_right
Descriptive, Comparative Study of Filipino Myelofibrosis Patients: An Agematched Comparison of Patients on Ruxolitinib vs. Best Available Therapy
Priscilla B Caguioa
Journal of Hematology & Thromboembolic Diseases, 2014
View PDFchevron_right
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms
Ahmad Zarzour
Therapeutic Advances in Hematology, 2012
View PDFchevron_right
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
Caroline Marty
F1000Research
View PDFchevron_right
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
Mariolina Iovine
Cancer Medicine, 2019
View PDFchevron_right